Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) have been given a consensus rating of “Moderate Buy” by the eight research firms that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $21.14.

A number of research firms have recently weighed in on YMAB. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price target on shares of Y-mAbs Therapeutics in a research note on Tuesday, August 13th. Wedbush reissued an “outperform” rating and issued a $23.00 price objective on shares of Y-mAbs Therapeutics in a research note on Tuesday, September 10th. Cantor Fitzgerald reissued an “overweight” rating and issued a $20.00 price objective on shares of Y-mAbs Therapeutics in a research note on Monday, September 9th. BMO Capital Markets cut their price objective on Y-mAbs Therapeutics from $26.00 to $25.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 13th. Finally, Canaccord Genuity Group raised Y-mAbs Therapeutics to a “strong-buy” rating in a research note on Tuesday, August 13th.

Insider Transactions at Y-mAbs Therapeutics

In other news, COO Joris Wilms sold 5,000 shares of Y-mAbs Therapeutics stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $14.69, for a total transaction of $73,450.00. Following the sale, the chief operating officer now owns 30,600 shares of the company’s stock, valued at approximately $449,514. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, COO Joris Wilms sold 5,000 shares of the business’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $14.69, for a total value of $73,450.00. Following the sale, the chief operating officer now owns 30,600 shares of the company’s stock, valued at $449,514. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Thomas Gad sold 30,000 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $12.97, for a total value of $389,100.00. Following the completion of the sale, the insider now directly owns 67,681 shares in the company, valued at approximately $877,822.57. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 100,000 shares of company stock valued at $1,338,100. 21.50% of the stock is owned by corporate insiders.

Institutional Trading of Y-mAbs Therapeutics

Several institutional investors have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. raised its position in Y-mAbs Therapeutics by 66.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company’s stock valued at $113,000 after purchasing an additional 3,416 shares during the last quarter. SG Americas Securities LLC bought a new position in Y-mAbs Therapeutics in the 3rd quarter valued at $178,000. Millennium Management LLC raised its position in Y-mAbs Therapeutics by 23.8% in the 2nd quarter. Millennium Management LLC now owns 349,784 shares of the company’s stock valued at $4,225,000 after purchasing an additional 67,233 shares during the last quarter. Squarepoint Ops LLC raised its position in Y-mAbs Therapeutics by 143.4% in the 2nd quarter. Squarepoint Ops LLC now owns 126,389 shares of the company’s stock valued at $1,527,000 after purchasing an additional 74,452 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in Y-mAbs Therapeutics in the 2nd quarter valued at $297,000. Institutional investors and hedge funds own 70.85% of the company’s stock.

Y-mAbs Therapeutics Stock Down 1.1 %

NASDAQ:YMAB opened at $14.48 on Friday. Y-mAbs Therapeutics has a 1-year low of $4.69 and a 1-year high of $20.90. The firm has a market capitalization of $635.43 million, a price-to-earnings ratio of -29.55 and a beta of 0.70. The stock has a fifty day simple moving average of $13.92 and a 200 day simple moving average of $13.15.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.08). Y-mAbs Therapeutics had a negative return on equity of 24.88% and a negative net margin of 28.44%. The business had revenue of $22.80 million during the quarter, compared to analysts’ expectations of $23.09 million. During the same period in the prior year, the company posted ($0.14) earnings per share. Equities analysts predict that Y-mAbs Therapeutics will post -0.6 earnings per share for the current year.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.